**ABSTRACT**

This paper presents the production and kinetic and inhibitory characterisation of β-carbonic anhydrase from the opportunistic bacterium *Staphylococcus aureus* (SauBCA). From the eight different carbonic anhydrase (CA) families known to date, humans have only the α-form, whereas many clinically relevant pathogens have β- and/ or γ-form(s). Based on this discovery, β- and γ-CAIs have been introduced as promising new anti-infective targets. The results of this study revealed that recombinant SauBCA possesses significant CO$_2$ hydration activity with a $k_{cat}$ of $1.46 \times 10^3$ s$^{-1}$ and a $k_{cat}/K_M$ of $2.56 \times 10^7$ M$^{-1}$ s$^{-1}$. Its enzymatic function was inhibited by various sulphonamides in the nanomolar – micromolar range, and the $K_i$ of acetazolamide was 628 nM. The best inhibitor was the clinically used sulfamide agent famotidine ($K_i$ of 71 nM). The least efficient inhibitors were zonisamide and dorzolamide. Our work encourages further investigations of SauBCA in an attempt to discover novel drugs against *Staphylococcus aureus* infections.

**KEYWORDS**

β-carbonic anhydrase; *Staphylococcus aureus*; kinetics; inhibition; sulphonamides

**INTRODUCTION**

*Staphylococcus* species represent a significant part of our microbiota, e.g. on our skin and in our mouth and gut. Most of these species are harmless, commensal bacteria that do not cause inflammation (e.g. *S. epidermidis*). However, one particular strain of *staphylococci* has been at the centre of attention since our first encounter with it over a century ago. Despite huge improvements in health care, *Staphylococcus aureus* has caused increasing morbidity and, in some cases, mortality. Due to the emergence of multi-drug-resistant strains (collectively termed MRSA, i.e. methicillin-resistant *S. aureus*), treatment has remained particularly challenging. The first nosocomial MRSA emerged not too long after Ian Fleming discovered penicillin, and more strains have emerged, causing it to be one of the most prominent causative agents of surgical-site infections and invasive bacterial diseases. In the past 20 years, *S. aureus* infections have increased dramatically, causing an increase in MRSA strains displaying resistance to penicillin-derived β-lactam antibiotics. The antibiotic resistance of MRSA is based on the single gene mecA, which encodes a penicillin inactivating enzyme on the surface of the bacteria. In addition, the virulence of *staphylococci* is based on their ability to attach to foreign bodies by specialised adhesins and form a biofilm to shield itself from antibiotics. MRSA is particularly resilient in hospital settings, where patients with diseases such as type I diabetes, immunodeficiencies or ongoing haemodialysis are at the greatest risk of acquiring the infection. Most cases occur through hospital personnel who are infected by their own reservoir or by infected patients. The infection requires physical contact and is activated when the skin or mucosal barrier is breached, allowing the bacteria to enter adjoining tissues or the bloodstream. Infections vary from mild skin lesions to severe cases of sepsis, endocarditis, osteomyelitis and pneumonia. Not all individuals show signs of *S. aureus* infection; hence, it can easily be passed on unnoticed via the skin in addition to from surgical instrumentation and other inanimate surfaces.

Novel innovative therapies are not only needed but also quickly becoming a necessity as the number of antibiotic-resistant pathogen strains increases. Scientists worldwide are thus exploring novel strategies for the prevention of these most threatening pathogenic infections. Among the promising biomolecular targets are carbonic anhydrases (CAs), a group of metalloenzymes found in all lifeforms. These vitally important enzymes catalyse a reversible reaction in which CO$_2$ is converted to bicarbonate ions and protons. This simple reaction is responsible for numerous vital cellular functions, such as acid-base homeostasis, CO$_2$ transportation, and photosynthesis. Among the eight evolutionarily divergent but functionally convergent CA gene families ($\alpha$, $\beta$, $\gamma$, $\delta$, $\zeta$, $\eta$, $\theta$, and $\iota$), humans have only the $\alpha$-forms. Interestingly, numerous pathogen strains have been identified with only $\beta$- and/or $\gamma$-CAs genes in their genome. This has been regarded as a promising starting point for discovering novel, specific anti-infectives against pathogens. The fundamental differences discovered between the active sites of different CA families support the idea of specifically targeting $\beta$- and/or $\gamma$-CAs with minimal effects on human $\alpha$-CAs. Numerous studies have been conducted demonstrating the efficiency of sulphonamides and anions as CA inhibitors (CAIs). Detailed characterisation of druggable CAs is considered a prerequisite for the design of more specific and efficient CAIs.
To date, several crystal structures of pathogenic β-CAs have been solved and can consequently be exploited for more efficient CAI design. Such structure-based design allows for in vivo targeted therapeutics against pathogenic diseases without the disadvantage of affecting the human or other mammalian CAs.

In the present study, we produced and isolated a novel β-CA from S. aureus (SauBCA) as a recombinant protein and tested its kinetic properties and inhibition profile against several known sulphonamides. Our results demonstrate that SauBCA represents a druggable enzyme target that should be further tested both in vitro and in vivo using different classes of potential CA inhibitors.

**Materials and methods**

**Protein production**

The SauBCA gene, obtained from the Universal Protein Resource Database (UniProt, protein entry EZX1576740), was cloned into the expression vector pBVboostFG by GeneArt (Thermo Fisher Scientific, Germany). The synthesised insert was composed of Gateway-compatible recombination sites (attL1 and attL2), Shine-Dalgarno and Kozak sequences, N-terminal 6×His-tag with surrounding spacer regions (MSTT and ATAIPTT42), SauBCA, and a thrombin cleavage site (LVPRGS)43. Chemically competent E. coli (OneShot® BL21 Star™ (DE3) cells, #C601003, Thermo Fisher Scientific) were transformed according to the Thermo Fisher Scientific OneShot® BL21(DE3) competent cells manual (part no. 28–0182). The culture medium used was Luria-Bertani (LB) supplemented with 10 mg/mL gentamicin (1:1000, v/v). The cells were grown in a fermenter at 28 °C for 12 h and subsequently induced by adding 1 mM isopropyl β-D-1-isopropyl-thiogalactopyranoside (IPTG). After another 12 h of culture at 25 °C, the cells were harvested by centrifugation at 4000 g for 40 min at 4 °C and mechanically disrupted with an EmulsiFlex-C3 homogeniser (AVESTIN, Canada). Subsequently, the cells were centrifuged at 13000 g for 20 min at 4 °C, and the supernatant was mixed with Protino® Nickel-nitrilotriacetic acid (Ni2+-NTA) agarose affinity chromatography resin (Macherey-Nagel GmbH Co., Germany) and 50 mM Na2HPO4, 0.5 M NaCl and 50 mM imidazole binding buffer (BB; pH 8.0). The incubation took place for 2 h at room temperature (RT) with gentle agitation, followed by overnight incubation at 4 °C without agitation. The resin was loaded into a chromatography column with an EMD Millipore™ vacuum filtering flask (Merck, #XX1004705) and washed generously with BB. The protein was eluted from the column with 50 mM Na2HPO4, 0.5 M NaCl and 350 mM imidazole (pH 7.0). After elution, the eluted fractions were analysed with reducing sodium dodecyl sulphate gel electrophoresis (SDS-PAGE) using a 12% (w/v) polyacrylamide gel and visualised with PageBlue protein staining solution (Thermo Fisher Scientific, #24620). The polypeptide bands on SDS-PAGE were used to identify the protein by means of tandem mass spectrometry (MS/MS, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Finland). A 6×His-tag was enzymatically cleaved using thrombin (#RECOMT, Sigma-Aldrich) according to the Thrombin CleanClive™ kit manual instructions (Sigma-Aldrich). The tag was separated from the core protein with Ni2+-NTA affinity chromatography as mentioned above. Prior to further characterisation, the buffer was exchanged for 50 mM Tris-Cl (pH 7.5).

**Kinetics and inhibition studies**

An Applied Photophysics stopped-flow instrument was used for assaying CA-catalysed CO2 hydration activity44. Phenol red (at a concentration of 0.2 mM) was used as the pH indicator at the absorbance maximum of 557 nm with 20 mM TRIS (pH 8.4) as the buffer with 20 mM Na2SO4 (for maintaining constant ionic strength) and following the initial rates of the CA-catalysed CO2 hydration reaction for over the period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and sulphonamide inhibition constants. Six traces of the initial 5–10% of the reaction were used to determine the initial velocity. The uncatalysed rates were determined in the same manner and subtracted from the total observed rates. A stock solution of inhibitor (0.1 mM) was prepared in distilled-deionized water, and dilutions of up to 0.01 mM were prepared thereafter with distilled-deionized water. Inhibitor (I) and enzyme (E) solutions were preincubated together for 15 min at RT prior to the assay to allow formation of the E–I complex. Inhibition constants were obtained by using the Cheng-Prusoff equation and nonlinear least squares methods (with PRISM 3) and are presented as the means from at least three different determinations. Kinetic constants were obtained using Lineweaver-Burke plots as reported earlier45–47.

**Results and discussion**

**Protein production**

A single β-CA enzyme of S. aureus was identified from the UniProt database40 and named SauBCA. The enzyme was successfully expressed in E. coli and purified by affinity chromatography. SDS-PAGE was used to monitor the purification process and successful cleavage of the His-tag. The tag was cleaved prior to further characterisation experiments. The gel from SDS-PAGE was stained with PageBlue and is shown in Figure 1. The relative molecular mass of the major band seen on the gel after His-tag removal corresponded to approximately 21 kDa. The theoretical molecular mass of SauBCA was calculated to be 21.1 kDa, suggesting that the...
**Table 1.** Kinetic data of SauBCA and the inhibition results for the standard sulphonamide inhibitor acetazolamide (AAZ). All human isozymes\(^{22,24}\) and two other \(\beta\text{-CA}\) isozymes\(^{25,40}\) with corresponding properties are shown for comparison. The \(k_{\text{cat}}\) and \(k_{\text{cat}}/K_m\) values are rounded to one decimal place.

| Enzyme                    | \(k_{\text{cat}}\) (s\(^{-1}\)) | \(k_{\text{cat}}/K_m\) (s\(^{-1}\)M\(^{-1}\)) | \(K_i\) (nM) |
|---------------------------|-------------------------------|---------------------------------|-----------|
| SauBCA                    | 1.5 \times 10^5              | 2.6 \times 10^5                 | 628       |
| hCA I                     | 2.0 \times 10^5              | 5.0 \times 10^5                 | 250       |
| hCA II                    | 1.4 \times 10^5              | 1.5 \times 10^5                 | 12        |
| hCA III                   | 1.3 \times 10^4              | 2.5 \times 10^4                 | 240000    |
| hCA IV                    | 1.1 \times 10^4              | 5.1 \times 10^4                 | 74        |
| hCA VA                    | 2.9 \times 10^4              | 2.9 \times 10^4                 | 63        |
| hCA VB                    | 9.5 \times 10^4              | 9.8 \times 10^4                 | 54        |
| hCA VI                    | 3.1 \times 10^4              | 4.9 \times 10^4                 | 11        |
| hCA VII                   | 9.5 \times 10^5              | 8.3 \times 10^5                 | 2.5       |
| hCA IX                    | 1.1 \times 10^5              | 1.5 \times 10^5                 | 16        |
| hCA XII                   | 4.2 \times 10^4              | 3.5 \times 10^4                 | 5.7       |
| hCA XIII                  | 1.5 \times 10^5              | 1.1 \times 10^5                 | 16        |
| hCA XIV                   | 3.1 \times 10^4              | 3.9 \times 10^4                 | 41        |
| *Burkholderia pseudomallei* \(\beta\text{-CA}\) | 1.6 \times 10^5              | 3.4 \times 10^5                 | 745       |
| *Flaveria bidentis* \(\beta\text{-CA}\) | 1.2 \times 10^4              | 7.5 \times 10^4                 | 27        |

**Table 2.** Inhibition data for SauBCA and hCA II with sulphonamide analogues 1–24 and selected clinically used agents.

| Inhibitor         | SauBCA | hCA II \(^a\) |
|-------------------|--------|---------------|
| **K\(_i\)** (nM) |        |               |
| 1                 | 355    | 300           |
| 2                 | 409    | 240           |
| 3                 | 95     | 8             |
| 4                 | 83     | 320           |
| 5                 | 193    | 170           |
| 6                 | 253    | 160           |
| 7                 | 93     | 60            |
| 8                 | 95     | 110           |
| 9                 | 75     | 40            |
| 10                | 202    | 54            |
| 11                | 81     | 63            |
| 12                | 79     | 75            |
| 13                | 417    | 60            |
| 14                | 553    | 19            |
| 15                | 619    | 80            |
| 16                | 603    | 94            |
| 17                | 232    | 125           |
| 18                | 555    | 46            |
| 19                | 909    | 33            |
| 20                | 92     | 2             |
| 21                | 85     | 11            |
| 22                | 83     | 46            |
| 23                | 92     | 33            |
| 24                | 96     | 30            |
| AAZ               | 628    | 12            |
| MZA               | 863    | 14            |
| EZA               | 698    | 8             |
| DZA               | 909    | 9             |
| BRZ               | 815    | 3             |
| BZA               | 501    | 9             |
| TPM               | 466    | 10            |
| ZNS               | 4551   | 35            |
| SLP               | 807    | 40            |
| IND               | 588    | 15            |
| VLX               | 509    | 43            |
| CLX               | 871    | 21            |
| SLT               | 824    | 9             |
| SAC               | 667    | 5959          |
| HCT               | 593    | 290           |
| FAM               | 71     | 58            |
| EPA               | 538    | 917           |

\(^{a}\)Mean from three different assays measured by the stopped-flow technique. Errors were in the range of ±5–10% of the reported values (data not shown).

purification procedure yielded the correct protein. This was further confirmed by MS/MS analysis, where three major polypeptides were analysed and identified as SauBCA. The relatively strong ~52 kDa polypeptide seemed to represent a dimeric form of the protein.

**Kinetics**

The obtained kinetic parameters for SauBCA are shown in Table 1 together with human \(\alpha\text{-CA}\) isozymes and other representative \(\beta\text{-CA}\)s for comparison. Kinetic analysis of SauBCA revealed that it is a moderately efficient enzyme with a \(k_{\text{cat}}\) of 1.46 \times 10^5 s\(^{-1}\) and \(k_{\text{cat}}/K_m\) of 2.56 \times 10^5 s\(^{-1}\)M\(^{-1}\). SauBCA showed kinetic properties fairly similar to several human CA isozymes, such as CA I, CA VA, CA VI, CA XII, CA XIII, and CA XIV. Notably, the \(k_{\text{cat}}\) value of SauBCA was identical to that of hCA XIII, whereas it was the most different from the clinically relevant isozymes hCA II and hCA IX, as well as to the low activity enzyme hCA III. Similar kinetics were observed with the \(\beta\text{-CA}\s\) from *Burkholderia pseudomallei* and *Flaveria bidentis*. As seen in Table 1, the binding affinities of SauBCA and *Burkholderia pseudomallei* \(\beta\text{-CA}\) to acetazolamide (AAZ) are rather similar, whereas the inhibition constant for *Flaveria bidentis* \(\beta\text{-CA}\) is very different. This finding suggests major structural differences in the active sites of these \(\beta\text{-CA}\) enzymes.

**Inhibition studies**

A set of clinically used sulphonamide drugs and sulphonamide analogues were investigated against SauBCA. The obtained inhibition constants can be seen in Table 2, along with the results from human \(\alpha\text{-CA}\) isofrom II for comparison. The molecular structures of sulphonamides 1–24 and of the clinically used agents tested in this study are shown in Figure 2.

SauBCA was successfully inhibited by selected sulphonamide analogues 1–24 and standard sulphonamide inhibitors AAZ-epacodastat (EPA) in the nanomolar range. In general, all studied compounds resulted in strong to medium \(K_i\) values spanning between 71 and 4551 nM. The most efficient inhibition was obtained with sulphonamide analogues 9, 11, 12, 21, 22, 24 and famotidine (FAM). Their inhibition affinities were < 100 nM, which indicates strong inhibition against the SauBCA catalytic function. The least efficient inhibitors were the following sulphonamides: zonisamide (ZNS), dorzolamide (DZA), 19, celecoxib (CLX), methylazolamide (MZA), sulthiame (SLT), and brinzolamide (BRZ). Despite showing the lowest efficiency in this study, their inhibition can still be regarded as medium/medium-weak. AAZ ranked 29th out of 41 studied sulphonamides with a \(K_i\) of 628 nM. In general, the clinically used sulphonamides showed inferior inhibition compared to designed sulphonamide analogues 1–24, except for FAM, which was in fact the most effective inhibitor. However, FAM (together with EPA) are the only sulamamide derivatives in the series, and FAM has a quite diverse scaffold compared to the other clinically used drugs investigated here. It has a large aliphatic fragment present in the structure, which is absent in the other compounds investigated in this study. Future work entails the design of more potent inhibitors against SauBCA.
Conclusion

In the current study, we successfully produced recombinant SauBCA and investigated its kinetics and inhibition profile with sulphonamides. The data showed that SauBCA possesses significant catalytic activity with a $k_{cat}$ of $1.46 \times 10^5 \text{s}^{-1}$ and $k_{cat}/K_M$ of $2.56 \times 10^7 \text{M}^{-1} \text{s}^{-1}$. The successful inhibition of SauBCA with selected sulphonamides in the nanomolar range warrants further investigation of potent SauBCA inhibitors for developing future anti-infective agents against staphylococcal infections. One of the most effective inhibitors detected in the study was famotidine, a clinically used antiulcer drug, with a $K_i$ of 71 nM.

Author contributions

All authors designed and conceived the experiments. LJU, MK, SB and AA performed the experiments. All authors analysed the data. LJU wrote the first draft of the manuscript. All authors have given approval to the final version of the manuscript.

Disclosure statement

The authors do not declare any conflicts of interest.

Funding

This research was supported by funding from the Academy of Finland and Jane & Aatos Erkko Foundation.

ORCID

Andrea Angeli http://orcid.org/0000-0002-1470-7192
Claudiu T. Supuran http://orcid.org/0000-0003-4262-0323
Seppo Parkkila http://orcid.org/0000-0001-7323-8536

References

1. Casewell MW, Hill RL. The carrier state: methicillin-resistant staphylococcus aureus. J Antimicrob Chemother 1986; 18(Suppl A):1–12.
2. Noble WC, Valkenburg HA, Wolters CH. Carriage of staphylococcus aureus in random samples of a normal population. J Hyg (Lond) 1967;65:567–73.
3. Microbiota of the human body. Advances in experimental medicine and biology. Switzerland, Cham: Springer.
4. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520–32.
5. Keynan Y, Rubinstein E. *Staphylococcus aureus* bacteraemia, risk factors, complications, and management. Crit Care Clin 2013;29:547–62.

6. Chatterjee SS, Otto M. Improved understanding of factors driving methicillin-resistant *staphylococcus aureus* epidemic waves. Clin Epidemiol 2013;5:205–17.

7. Deurenberg RH, Stobberingh EE. The evolution of *staphylococcus aureus*. Infect Genet Evol 2008;8:747–63.

8. Petti CA, Sanders LL, Trivette SL, et al. Postoperative bacteraemia secondary to surgical site infection. Clin Infect Dis 2002;34:305–8.

9. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant *staphylococcus aureus*, united states, 1999–2005. Emerging Infect Dis 2007;13:1840–6.

10. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive mrsa infections, 2005–2008. JAMA 2010;304:641–8.

11. Fuda CC, Fisher JF, Mobashery S. Beta-lactam resistance in *staphylococcus aureus*: the adaptive resistance of a plastic genome. Cell Mol Life Sci 2005;62:2617–33.

12. Tong SYC, Davis JS, Eichenberger E, et al. How long do nosocomial *Staphylococcus* bacteremia persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6:(130

13. Berger-Bachi B. Genetic basis of methicillin resistance in *Staphylococcus aureus*. Cell Mol Life Sci 1999;56:764–70.

14. Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. Expression and inducibility in *staphylococcus aureus* of the meca gene, which encodes a methicillin-resistant s. Aureus-specific penicillin-binding protein. J Bacteriol 1989;171:2882–5.

15. Guyot A, Layer G. MRSA - ‘bug-bear’ of a surgical practice: reducing the incidence of MRSA surgical site infections. Ann R Coll Surg Engl 2006;88:222–3.

16. Jacobson MA, Gellermann H, Chambers H. *Staphylococcus aureus* bacteraemia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and aids-related complex. Am J Med 1988;85:172–6.

17. Tuazon CU, Perez A, Kishaba T, Sheagren JN. *Staphylococcus aureus* among insulin-injecting diabetic patients. An increased carrier rate. Jama 1975;231:1272.

18. Sherez RJ, Reagan DR, Hampton KD, et al. A cloud adult: the *staphylococcus aureus*-virus interaction revisited. Ann Intern Med 1996;124:539–47.

19. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6(130

20. Supuran CT. Bortezomib inhibits bacterial and fungal beta-carboxydrases. Bioorg Med Chem 2016;24:4406–9.

21. Innocenti A, Hall RA, Schlicker C, et al. Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens candida albicans and cryptococcus neoformans with aliphatic and aromatic carboxylates. Bioorg Med Chem 2009;17:2654–7.

22. Schlicker C, Hall RA, Vullo D, et al. Structural mapping of anion inhibitors to beta-carboxydrase psCA3 from Pseudomonas aeruginosa. ChemMedChem 2018;13:204–9.

23. Ferraroni M, Del Prete S, Vullo D, et al. Crystal structure and kinetic studies of a tetrameric type ii beta-carboxydrase from the pathogenic bacterium *Vibrio cholerae*. Acta Crystallogr D Biol Crystallogr 2015;71:2449–56.

24. Del Prete S, Vullo D, De Luca V, et al. Sulfonamide inhibition studies of the beta-carboxydrase from *Helicobacter pylori* is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007;17:3585–94.

25. Syrjanen L, Kuuslahti M, Tolvanen M, et al. The beta-carboxydrase from the malaria mosquito *Anopheles gambiae* is highly inhibited by sulfonamides. Bioorg Med Chem 2015;23:2303–9.

26. Vullo D, Del Prete S, Di Fonzo P, et al. Comparison of the sulfonamide inhibition profiles of the beta- and gamma-carboxydrases from the pathogenic bacterium *Burkholderia pseudomallei*. Molecules 2017;22:421.

27. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem 2016;24:4406–9.

28. Claudiu TS. Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 2007;7:825–33.

29. Supuran CT. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Disc 2008;7:168–81.

30. Kikutani S, Nakajima K, Nagasato C, et al. Thylakoid luminal beta-carboxydrase critical for growth and photosynthesis in the marine diatom *Phaeodactylum tricornutum*. Proc Natl Acad Sci USA 2016;113:9828–33.

31. Jensen EL, Clement R, Kosta A, et al. A new widespread sub-class of carbonic anhydrase in marine phytoplankton. ISME J 2019;13:2094–106.
42. Piao S, Xu Y, Ha NC. Crystallization and preliminary x-ray crystallographic analysis of MacA from *Actinobacillus actinomyctemcomitans*. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008;64:391–3.

43. Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of ca ix, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799–809.

44. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.

45. Del Prete S, Bua S, Supuran CT, Capasso C. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enz Inhib Med Chem 2020;35:1545–54.

46. Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020.

47. De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.

48. Hilvo M, Innocenti A, Monti SM, et al. Recent advances in research on the most novel carbonic anhydrases, ca xiii and xv. Curr Pharm Des 2008;14:672–8.

49. Monti SM, De Simone G, Dathan NA, et al. Kinetic and anion inhibition studies of a β-carbonic anhydrase (FbiCA 1) from the C4 plant *Flaveria bidentis*. Bioorg Med Chem Lett 2013;23:1626–30.